FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 568 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients... July 8, 2024 Percentage of Cancer Patients Who Are Eligible for and Respond to... April 15, 2021 FDA Approves Crizotinib for Children and Young Adults with Relapsed or... January 19, 2021 GPRC5D Is An Active Immunotherapeutic Target in Multiple Myeloma October 5, 2022 Load more HOT NEWS Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive... New on NCI’s Websites for March 2025 EMA Recommends Extension of Indications for Durvalumab Paralyzed Bride Walks Down Aisle At Her Wedding & Surprises Groom
